Nevertheless, the extensive use of immunosuppressants other than methotrexate as alternative treatment or pretreatment before considering TNF-inhibitors may also affect the risk for malignancies and should be avoided.”
Dr. Horneff disclosed having financial relationships with a number of companies, including Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, Lilly, MedImmune, Merck Serono, Novartis, Nycomed, Pfizer, Roche, Sandoz, and Wyeth.